Manulife strengthens cooperation with CUHK Medical Centre to incorporate fragmented technology into treatment options

Manulife has strengthened its cooperation with The Chinese University of Hong Kong (CUHK) Medical Centre to incorporate fragmentation technology into its health insurance plans, providing innovative therapies for cancer patients. This technology is an FDA-approved non-invasive treatment aimed at providing efficient options for liver cancer patients. The service will be implemented once the technology is available to the public, and patients will need to participate in clinical trials to monitor outcomes. Manulife has established a partnership with CUHK Medical Centre since 2021 to provide medical consultation and pre-approval services without co-payment